Stockreport

Adagene Provides Business Update and 2026 Objectives

Adagene Inc. - ADS, each representing 1.25 ordinary shares  (ADAG) 
PDF Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026 Unaudited cash and cash equivalents of [Read more]